

-----Original Message-----

From: XXX YYY<xxx@yyy.zzz>

Sent: Mon, Sep 16, 2013 at 10:05 AM

To: Managing Editor

Subject: RE: Request for evaluation of revised paper, reference number:  
2013\_BJMMR\_6088

I have read some data about the treatment of leukemia and consulted colleagues , if single **Doxorubicin** treatment of acute lymphoblastic leukemia, it is not in line with international guidelines, there is a big problem in the study, So I suggest rejection!

**Note: Modification was done in this document ONLY to hide the email id.**

**Reviewer Details:**

Name:	<b>Shaoling wu</b>
Department, University & Country	<b>Department of Hematology, The Affiliated Hospital of medical Colleg, Qingdao University, 16 Jiangsu Road, Qingdao, Shandong 266003, China.</b>